




ERNEST F. CHAPMAN
202-408-4096

January 9, 2002

ATTORNEY DOCKET NO. 03806.0533
CUSTOMER NO. 22,852



Box PATENT APPLICATION
Assistant Commissioner for Patents
Washington, DC 20231

New U.S. Patent Application

Title: CHEMICAL DERIVATIVES AND THEIR APPLICATION AS
ANTITELOMERASE AGENTS

Inventors Names and Residences:

1. Patrick MAILLIET, Fontenay Sous Bois, France;
2. Jean-François RIOU, Reims, France;
3. Marcel ALASIA, Choisy Le Roi, France;
4. Thomas CAULFIELD, Paris, France;
5. Gilles DOERFLINGER, Les Ulis, France;
6. Jean-Louis MERGNY, Villejuif, France;
7. Abdelazize LAOUI, Bridgewater, NJ;
8. Odile PETITGENET, Paris, France; and
9. Emmanuelle RENOU, Paris, France.

Sir:

We enclose the following papers for filing in the United States Patent and Trademark Office in connection with the above patent application.

1. Application- 51 pages, including 2 independent claims and 31 claims total.
2. Information Disclosure Statement and Information Disclosure Citation, PTO 1449 with 3 documents attached.
3. Sequence Listing - 2 pages.
4. Statement Regarding Submission of Computer Readable Form of Sequence Listing.
5. Sequence Listing Diskette.
6. The filing fee is calculated as follows:

Basic Application Filing Fee					\$740	\$ 740.00
	Number of Claims		Basic	Extra Claims		
Total Claims	31	-	20	11	x \$18	198.00
Independent Claims	2	-	3	0	x \$84	
<input type="checkbox"/> Presentation of Multiple Dep. Claim(s)					+\$280	
Subtotal						\$ 938.00
Reduction by 1/2 if small entity						-
TOTAL APPLICATION FILING FEE						\$ 938.00

7. A check for \$938.00 is enclosed. The fee includes:

\$740.00 filing fee; and
\$198.00 additional claims fee

This application is being filed under the provisions of 37 C.F.R. § 1.53(f). Applicants await notification from the Patent and Trademark Office of the time set for filing the Declaration.

Applicants claim the right to priority based on French Application No. 01 00205, filed January 9, 2001 and the benefit of U.S. Provisional Application No. 60/270,164, filed February 22, 2001.

Please address all correspondence with respect to this application to:

Finnegan, Henderson, Farabow, Garrett & Dunner, L.L.P.
1300 I Street, N.W.
Washington, D.C. 20005-3315

Please accord this application an application number and filing date.

The Commissioner is hereby authorized to charge any additional filing fees due and any other fees due under 37 C.F.R. § 1.16 or §1.17 during the pendency of this application to our Deposit Account No. 06-0916.

Respectfully submitted,
FINNEGAN, HENDERSON, FARABOW,
GARRETT & DUNNER, L.L.P.

By: 
Ernest F. Chapman
Reg. No.25,961

EFC/FPD/peg
Enclosures

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)
)
Mailliet, *et al.*) Group Art Unit: To Be Assigned
)
Serial No.: To Be Assigned) Examiner: To Be Assigned
)
Filed: January 9, 2002)
)
For: Chemical Derivatives and Their)
Application as Antitelomerase)
Agents)

10925 U.S. PTO
10/040370
01/09/02

Commissioner for Patents and Trademarks
Washington, DC 20231

Sir:

**STATEMENT REGARDING SUBMISSION OF
COMPUTER READABLE FORM OF SEQUENCE LISTING**

In accordance with 37 C.F.R. § 1.821(f), the undersigned verifies that the information recorded on the computer readable form of the sequence listing is identical to the information in the paper copy of the sequence listing. No new matter is included with this submission.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,
GARRETT & DUNNER, L.L.P.

By:

M. Todd Rands
Reg. No. 46,249

Dated: January 8, 2002